<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517033</url>
  </required_header>
  <id_info>
    <org_study_id>PK-12-151</org_study_id>
    <nct_id>NCT03517033</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet</brief_title>
  <official_title>An Open Label, Randomized, 2 -Period, 2 -Treatment, 2- Sequence, Crossover, Single-Dose BE Study of Nebivolol 20 mg Tablet [Torrent, India] Vs Bystolic® 20 mg Tablet [ Forest Pharmaceuticals Inc., USA] in Healthy Subjects Fed Condition.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and&#xD;
      Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were&#xD;
      separated by a washout period of 11 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open Label, Randomized, 2- Period, 2 -Treatment, 2 -Sequence, Crossover, Single- dose&#xD;
      Bioequivalence study of Nebivolol Tablets containing Nebivolol 20 mg (Test Formulation,&#xD;
      Torrent Pharmaceuticals Ltd., India) Versus Bystolic® 20 mg Tablets containing Nebivolol 20&#xD;
      mg (Reference, Forest Pharmaceuticals Ltd., USA) in Healthy Volunteers Under Fed Condition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>pre-dose to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>pre-dose to 72 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Torrent's Nebivolol Tablets 20 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Forest Pharmaceuticals Inc's Bystolic Tablets 20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torrent's Nebivolol Tablets</intervention_name>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Forest Pharmaceuticals Inc.'s Bystolic Tablets</intervention_name>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sex: male&#xD;
&#xD;
          -  Age: 18-45 years (inclusive both)&#xD;
&#xD;
          -  Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.&#xD;
&#xD;
          -  Healthy and willing to participate in the study.&#xD;
&#xD;
          -  Volunteer willing to adhere to the protocol requirements and to provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Non-smokers or smoker who smokes less than 10 cigarettes per day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to communicate or co-operate.&#xD;
&#xD;
          -  Volunteers suffering from any chronic illness such as arthritis, asthma etc.&#xD;
&#xD;
          -  History of pre-existing bleeding disorder.&#xD;
&#xD;
          -  Clinically relevant abnormalities in the results of the laboratory screening&#xD;
             evaluation.&#xD;
&#xD;
          -  Clinically significant abnormal ECG or Chest X-ray.&#xD;
&#xD;
          -  HIV, HCV, HBsAg positive volunteers.&#xD;
&#xD;
          -  History of significant blood loss due to any reason, including blood donation in the&#xD;
             past 3 months.&#xD;
&#xD;
          -  Participation in any study within past 3 months before entry to the study,&#xD;
&#xD;
          -  History of alcohol or drug abuse.&#xD;
&#xD;
          -  History of consumption of prescribed medication since last 14days or OTC medication/&#xD;
             herbal remedies since last 7 days before beginning of the study.&#xD;
&#xD;
          -  Positive to breath alcohol test.&#xD;
&#xD;
          -  Volunteer found to be positive for Opiate, tetra hydrocannabinol, amphetamine,&#xD;
             barbiturates, benzodiazepines, Cocaine positive volunteers based on urine test.&#xD;
&#xD;
          -  Systolic blood pressure less than 100 mmHg or more than 140 mmHg and diastolic blood&#xD;
             pressure less than 60 mm Hg or more than 90 mm Hg.&#xD;
&#xD;
          -  Pulse rate less than 50/minute or more than 100/minute.&#xD;
&#xD;
          -  Oral temperature less than 95°F or more than 98.6°F.&#xD;
&#xD;
          -  Respiratory rate less than 12/minute or more than 20/minute.&#xD;
&#xD;
          -  History of allergy to the test drug or any drug chemically similar to the drug under&#xD;
             investigation.&#xD;
&#xD;
          -  Recent History of kidney or liver dysfunction.&#xD;
&#xD;
          -  Volunteers suffering from any psychiatric (acute or chronic) disorder.&#xD;
&#xD;
          -  Existence of any surgical or medical condition, which, in the judgment of the Chief&#xD;
             Investigator and/or clinical investigator/physician, might interfere with the&#xD;
             absorption; distribution,· metabolism or excretion of the drug or likely to compromise&#xD;
             the safety of Volunteers.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

